Stanford University
Showing 21-30 of 49 Results
-
John P.A. Ioannidis
George E. and Lucy Becker Professor of Medicine, Professor of Epidemiology and Population Health and, by courtesy, of Biomedical Data Science
Current Research and Scholarly InterestsMeta-research
Evidence-based medicine
Clinical and molecular epidemiology
Human genome epidemiology
Research design
Reporting of research
Empirical evaluation of bias in research
Randomized trials
Statistical methods and modeling
Meta-analysis and large-scale evidence
Prognosis, predictive, personalized, precision medicine and health
Sociology of science -
Esther M. John
Professor (Research) of Epidemiology and Population Health and of Medicine (Oncology)
Current Research and Scholarly InterestsDr. John has extensive expertise in conducting population-based epidemiologic studies and has led as Principal Investigator multiple large-scale studies, including multi-center studies with a study site in the San Francisco Bay Area with its diverse population. Many of her studies and collaborations investigated cancer health disparities. Her research has focused on the role of modifiable lifestyle factors (e.g., body size, physical activity, diet), hormonal factors, early-life exposures, genetic variants, and gene-environment interactions; differences in risk factors by race and ethnicity, breast cancer subtypes, and prostate cancer subtypes; risk factors for familial breast cancer and second primary breast cancer, as well as prognostic factors related to survival disparities.
As Principal Investigator, Dr. John has led a number of studies conducted in the San Francisco Bay Area, including:
- the Northern California site of the Breast Cancer Family Registry, an on-going prospective multi-generational cohort of over 13,000 families established in 1995 at six international sites;
- the San Francisco Bay Area Breast Cancer Study, a population-based case-control study in nearly 5,000 African American, Hispanic, and non-Hispanic White women that investigated the role of modifiable lifestyle factors and other risk factors;
- the California site of the Breast Cancer Health Disparities Study that investigated genetic variability and breast cancer risk and survival in Hispanic and non-Hispanic White populations in the context of genetic admixture;
- the Breast Cancer Etiology in Minorities (BEM) Study, a pooled analysis of risk factors for breast cancer subtypes in minoritized racial and ethnic populations;
- the Northern California site of the WECARE Study that investigates risk factors for second primary contralateral breast cancer;
- the Second Primary Breast Cancer Disparities Study, a pooled analysis of risk factors for contralateral and ipsilateral second primary breast cancer in a diverse population;
- the San Francisco Bay Area Prostate Cancer Study, a population-based case-control study of lifestyle and genetic risk factors for advanced and localized disease.
These studies collected and pooled extensive data and biospecimens and continue to support numerous ancillary studies, collaborations and international consortia and have contributed to a better understanding of cancer risk and survival in minoritized racial and ethnic populations.
Dr. John is a founding PI of the LEGACY Girls Study, a prospective cohort established in 2011 that investigates early life exposures in relation to pubertal development outcomes, breast tissue characteristics, and behavioral and psychosocial outcomes in the context of having a family history or breast cancer.
In 2023, Dr. John joined the Stanford investigator team of the MOSAAIC (The Multiethnic Observational Study in American Asian and Pacific Islander Communities) Study, a five-center study to improve health of American Asian, Native Hawaiian, and Pacific Islander populations. -
Abby C. King
David and Susan Heckerman Professor and Professor of Epidemiology & Population Health and of Medicine (Stanford Prevention Research Center)
Current Research and Scholarly InterestsMy interests include applications of behavioral theory and social ecological approaches to achieve large scale changes impacting chronic disease prevention and control; expanding the reach and translation of evidence-based interventions through state-of-the-art technologies; exploring social and physical environmental influences on health; applying community participatory research perspectives to address health disparities; and policy-level approaches to health promotion/disease prevention.
-
Allison W. Kurian, M.D., M.Sc.
Colleen Haas Chair in the School of Medicine, Professor of Medicine (Oncology) and of Epidemiology and Population Health
Current Research and Scholarly InterestsI aim to understand cancer burden and improve treatment quality at the population level. I have a strong focus on genetic risk assessment and precision oncology. I lead epidemiologic studies of cancer risk factors, clinical trials of novel approaches to genetic testing and cancer risk reduction, and decision analyses of strategies to optimize cancer outcomes.
-
Uri Ladabaum
Professor of Medicine (Gastroenterology and Hepatology)
Current Research and Scholarly InterestsGastrointestinal cancer prevention and risk management. Risk stratification. Cost-effectiveness analysis. Health services research.
-
Marvin Langston
Assistant Professor of Epidemiology and Population Health and, by courtesy, of Urology
BioDr. Marvin Langston is an Assistant Professor of Epidemiology and Population Health. He is a member of the Stanford Cancer Institute and Urologic Cancer Epidemiology Lab. He is an epidemiologist by training who focuses on the fields of benign prostate and pelvic conditions and urological cancers including prostate and kidney cancers.
Prior to Stanford, he served as a Research Scientist in the Division of Research at Kaiser Permanente Northern California. Dr. Langston received his PhD in Epidemiology from the University of Arizona’s College of Public Health followed by postdoctoral training in Cancer Prevention and Control at Washington University in Saint Louis School of Medicine.
His program of research intends to characterize and measure infectious agents, environmental toxicants, and lifestyle factors; to evaluate the role of these factors in urological cancer etiology and outcomes; and to identify populations at high risk of exposure to these factors. So far he has focused this research to address the following questions: 1) What role do sexually transmitted infections and other systemic infections have in prostate damage and ensuing prostate cancer risk? 2) How can we appropriately model and define early life risk factors for urological cancers? 3) Can we harmonize molecular and clinical aspects of urological condition diagnoses to produce well characterized outcomes for biomarker discovery and etiological investigation? He has primarily addressed these questions using a variety of molecular and clinical epidemiology approaches while developing expertise in the cross-cutting theme of cancer health disparities with particular interests in the cancer care experiences of sexual and gender minorities and racial/ethnic minorities.
Dr. Langston has been studying the impact of exogenous factors on prostate specific antigen (PSA) concentration in young men as a marker of prostate damage and inflammation for over a decade. As early life PSA has been found predictive of future prostate cancer mortality, he has now setout to optimize risk-stratified screening for prostate cancer. This promising approach uses men’s baseline PSA values to inform their risk of future aggressive and/or fatal prostate cancer and determine their frequency of further screening. Under this approach, men with high baseline age-specific total PSA levels receive more frequent screening and men with lower levels receive less frequent screening. Dr. Langston was awarded an R01 from NCI to evaluate this approach using historically collected biospecimen. His funded research trajectory to this point also includes four training awards (2-NCI and 2-NIDDK) and several internal grants. Dr. Langston was selected in the inaugural class of the White House Cancer Moonshot Scholars for his work. -
Jennifer Lee
Professor of Medicine (Endocrinology) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsI am a healthcare lead and physician scientist for innovation, R&D, and advanced analytics, and oversee these aspects at VA Palo Alto/VHA, within Stanford-VA relationship. The VA has the US's largest health care system and longest running EHR. I prioritize enabling multiple partners (industry, government, academia, foundations), to innovate/R&D in the VA health care system. We prioritize mentoring students from various Schools to become future leaders in R&D, innovation, and healthcare.
-
Eleni Linos, MD, MPH, DrPH
Ben Davenport and Lucy Zhang Professor of Medicine, Professor, of Medicine (Center for Digital Health) and, by courtesy, of Epidemiology and Population Health
BioEleni Linos MD, MPH, DrPH, is the Director of the Stanford Center for Digital Health. Dr. Linos serves as Associate Dean for Research and Professor of Dermatology and Epidemiology at Stanford Medicine.
Dr. Linos' research focuses on the use of technology in health, dermatology, public health, cancer prevention and the care of older adults. She is dually trained in epidemiology and dermatology and is the principal investigator of several NIH funded studies aimed at improving the lives of patients worldwide. She received her undergraduate degree from Trinity College, Cambridge and medical degree from Christ Church College, Oxford University in the UK. She then received a master’s and doctoral degree from the Harvard School of Public Health and completed her residency in Dermatology at Stanford University.
Linos has been continuously funded by the NIH since 2016, as principal investigator of several studies on technology, aging and dermatology. Her scholarly output includes over 200 peer-reviewed publications, an h-index of 51, and more than 10,000 citations across disciplines. Linos was awarded the NIH Director’s New Innovator Award and received the Paul Beeson Emerging Leaders Award in Aging.
As the Director of the Stanford Center for Digital Health, she has built and led infrastructure bringing together scientists and industry leaders across all Stanford schools to catalyze research across the fields of medicine, computer science, engineering, robotics, policy and public health.
Dr. Linos is committed to mentorship and training of the next generation of scientists in translational research. She has personally mentored over 60 physician-scientists, many of whom are now independently-funded investigators and leaders in academic medicine. She also serves as the co-PI of Stanford CTSA’s K12 Program, responsible for mentorship and training of 10 translational science faculty each year. Over the last seven years, she is funded by an NIH K24 mentorship grant award to mentor the next generation of physician-scientists in dermatology. In addition, Linos is committed to mentorship and supporting students across all levels of education to pursue their passions including students in high school and undergraduates.
Clinically, Dr. Linos is a Board Certified Dermatologist and cares for patients with skin disease in the Stanford Dermatology teaching clinics. -
Karl Lorenz
Professor of Medicine (Primary Care and Population Health)
BioDr. Karl Lorenz, MD MSHS is a general internal medicine and palliative care physician, and Section chief of the VA Palo Alto-Stanford Palliative Care Program. Formerly at the VA Greater Los Angeles, Dr. Lorenz directed palliative care research at the VA Center for Innovation to Implementation and served on the faculty at the UCLA School of Medicine. Dr. Lorenz is a member of the VA’s national Hospice and Palliative Care Program (HPC) leadership team, director of the operational palliative care Quality Improvement Resource Center (QuIRC), and adjunct facility staff member at RAND. Dr. Lorenz’s work and leadership has been influential to the field of palliative care research. Under Dr. Lorenz’s leadership, since 2009 the Quality Improvement Resource Center (QuIRC) has served as one of three national leadership Centers responsible for strategic and operational support of the VA’s national hospice and palliative care programs. QuIRC develops and implements provider facing electronic tools for the VA’s national electronic medical record to improve the quality of palliative care. In that role, Dr. Lorenz participates with the national leadership team in strategic planning, policy development, and providing resources to support operational efforts. Dr. Lorenz has contributed to the field of global palliative care, serving the World Health Organization in its development of Palliative Care for Older People and leading methods for Palliative Care Essential Medications.
